Open AccessP826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
Author(s) -
Kulasekararaj A.,
Füreder W.,
McDonald A.,
Malherbe J. L. R.,
Gandhi S.,
Collins D.,
Cornpropst M.,
Dobo S.,
Farmer M. K.,
Kargl D.,
Sheridan W.,
Griffin M.,
Risitano A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846188.51290.75
Subject(s) - paroxysmal nocturnal hemoglobinuria , medicine , tolerability , hemolysis , hemoglobinuria , adverse effect , gastroenterology , anesthesia